JP2020508063A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508063A5 JP2020508063A5 JP2019545954A JP2019545954A JP2020508063A5 JP 2020508063 A5 JP2020508063 A5 JP 2020508063A5 JP 2019545954 A JP2019545954 A JP 2019545954A JP 2019545954 A JP2019545954 A JP 2019545954A JP 2020508063 A5 JP2020508063 A5 JP 2020508063A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- cells
- csf1r
- domain
- cd40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 112
- 102000037865 fusion proteins Human genes 0.000 claims description 112
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 47
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 47
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 34
- 108010029697 CD40 Ligand Proteins 0.000 claims description 31
- 102100032937 CD40 ligand Human genes 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 25
- 101150013553 CD40 gene Proteins 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 20
- 108091011896 CSF1 Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 210000002540 macrophage Anatomy 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 101710165474 Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 210000003289 regulatory T cell Anatomy 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229940123189 CD40 agonist Drugs 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000000225 synapse Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 2
- 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 210000004322 M2 macrophage Anatomy 0.000 claims description 2
- 230000037453 T cell priming Effects 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 102000053925 human CSF1 Human genes 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 210000005008 immunosuppressive cell Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004941 influx Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 230000000770 proinflammatory effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 231100000440 toxicity profile Toxicity 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 230000002045 lasting effect Effects 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 210000003690 classically activated macrophage Anatomy 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 7
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 2
- -1 LIGHT Proteins 0.000 description 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 2
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003259 immunoinhibitory effect Effects 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022125121A JP2022159393A (ja) | 2017-02-27 | 2022-08-04 | Ｃｓｆ１ｒベースのキメラタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463997P | 2017-02-27 | 2017-02-27 | |
| US62/463,997 | 2017-02-27 | ||
| PCT/US2018/020039 WO2018157164A1 (en) | 2017-02-27 | 2018-02-27 | Csf1r-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125121A Division JP2022159393A (ja) | 2017-02-27 | 2022-08-04 | Ｃｓｆ１ｒベースのキメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508063A JP2020508063A (ja) | 2020-03-19 |
| JP2020508063A5 true JP2020508063A5 (enExample) | 2021-04-08 |
| JP7121029B2 JP7121029B2 (ja) | 2022-08-17 |
Family
ID=63253352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545954A Active JP7121029B2 (ja) | 2017-02-27 | 2018-02-27 | Ｃｓｆ１ｒベースのキメラタンパク質 |
| JP2022125121A Pending JP2022159393A (ja) | 2017-02-27 | 2022-08-04 | Ｃｓｆ１ｒベースのキメラタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022125121A Pending JP2022159393A (ja) | 2017-02-27 | 2022-08-04 | Ｃｓｆ１ｒベースのキメラタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US11267856B2 (enExample) |
| EP (1) | EP3585409A4 (enExample) |
| JP (2) | JP7121029B2 (enExample) |
| KR (1) | KR20190124247A (enExample) |
| CN (1) | CN110381974A (enExample) |
| AU (1) | AU2018223822A1 (enExample) |
| BR (1) | BR112019017713A2 (enExample) |
| CA (1) | CA3054132A1 (enExample) |
| IL (1) | IL268197A (enExample) |
| MX (1) | MX2019010173A (enExample) |
| PH (1) | PH12019501534A1 (enExample) |
| SA (1) | SA519402522B1 (enExample) |
| SG (1) | SG11201906464UA (enExample) |
| WO (1) | WO2018157164A1 (enExample) |
| ZA (1) | ZA201906235B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110381974A (zh) | 2017-02-27 | 2019-10-25 | 沙塔克实验室有限公司 | 基于csf1r的嵌合蛋白 |
| EP3930851A4 (en) * | 2019-02-28 | 2023-03-29 | Shattuck Labs, Inc. | Combination therapies |
| US20220259281A1 (en) * | 2019-06-21 | 2022-08-18 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| CN111068054B (zh) * | 2019-11-06 | 2022-02-11 | 浙江大学医学院附属第一医院 | 以csf1r作为药物靶点治疗肿瘤的药剂及其制备方法 |
| KR20220117320A (ko) * | 2019-12-24 | 2022-08-23 | 아다젠 (수저우) 리미티드 | 항 csf1r 분자 및 이의 용도 |
| KR102671409B1 (ko) * | 2021-03-02 | 2024-05-31 | 진화섭 | Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| KR20230012129A (ko) * | 2021-07-14 | 2023-01-26 | 주식회사 이뮤노로지컬디자이닝랩 | Cd30에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| CA2121798C (en) * | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
| JP4723782B2 (ja) | 2000-01-03 | 2011-07-13 | ティーアール アソシエイツ，エル．エル．シー． | 新規なキメラ蛋白質及び該蛋白質の使用方法 |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| US20080131431A1 (en) | 2006-05-15 | 2008-06-05 | Viral Logic Systems Technology Corp. | CD47 related compositions and methods for treating immunological diseases and disorders |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| WO2008061377A1 (en) | 2006-11-22 | 2008-05-29 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| AU2009223784A1 (en) | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2010005519A1 (en) | 2008-06-30 | 2010-01-14 | University Of Pennsylvania | Fn14/trail fusion proteins |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| US8183207B2 (en) * | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| CA2747678A1 (en) | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| CN102421913A (zh) | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| AU2011309689B2 (en) | 2010-09-28 | 2015-01-15 | Hadasit Medical Research Services & Development Ltd. | Compositions and methods for treatment of hematological malignancies |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| ES2608835T3 (es) * | 2011-04-13 | 2017-04-17 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| US10179164B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| AU2012369202A1 (en) | 2012-02-06 | 2014-09-25 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| EP4219536A3 (en) | 2012-04-30 | 2023-08-23 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| EP4053162A1 (en) | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| CN103566377A (zh) | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| EP2890398A4 (en) * | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R) |
| JP6335189B2 (ja) | 2012-12-17 | 2018-05-30 | トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ＳＩＲＰアルファ−Ｆｃ融合体でのＣＤ４７＋疾患細胞の治療 |
| CA2896989A1 (en) | 2013-01-01 | 2014-07-10 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| US9873747B2 (en) | 2013-01-31 | 2018-01-23 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| PT2970512T (pt) | 2013-03-12 | 2019-01-17 | Biocon Ltd | Proteínas de fusão imunomoduladoras e métodos para produção das mesmas |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| MX2016007965A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| CA2936244A1 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| CN106459218B (zh) | 2014-03-24 | 2021-03-02 | 宜明昂科生物医药技术（上海）有限公司 | 新的重组双功能融合蛋白、其制剂和用途 |
| BR112016027845A2 (pt) | 2014-05-29 | 2017-10-31 | Medimmune Llc | proteínas de fusão de ox40l e usos das mesmas |
| WO2015200828A1 (en) | 2014-06-27 | 2015-12-30 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| CN113621075B (zh) | 2014-08-08 | 2024-09-20 | Alx肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| WO2016024021A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| MX2017006320A (es) | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| LT3283527T (lt) | 2015-04-13 | 2021-03-25 | Five Prime Therapeutics, Inc. | Kompleksinė terapija vėžio gydymui |
| WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| WO2016187226A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| JP6898303B2 (ja) | 2015-08-07 | 2021-07-07 | エーエルエックス オンコロジー インコーポレイテッド | Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物 |
| CN116063566A (zh) * | 2015-10-01 | 2023-05-05 | 热生物制品有限公司 | 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法 |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| CN110381974A (zh) | 2017-02-27 | 2019-10-25 | 沙塔克实验室有限公司 | 基于csf1r的嵌合蛋白 |
-
2018
- 2018-02-27 CN CN201880014002.2A patent/CN110381974A/zh active Pending
- 2018-02-27 WO PCT/US2018/020039 patent/WO2018157164A1/en not_active Ceased
- 2018-02-27 EP EP18756880.3A patent/EP3585409A4/en active Pending
- 2018-02-27 MX MX2019010173A patent/MX2019010173A/es unknown
- 2018-02-27 JP JP2019545954A patent/JP7121029B2/ja active Active
- 2018-02-27 SG SG11201906464UA patent/SG11201906464UA/en unknown
- 2018-02-27 CA CA3054132A patent/CA3054132A1/en active Pending
- 2018-02-27 AU AU2018223822A patent/AU2018223822A1/en not_active Abandoned
- 2018-02-27 BR BR112019017713A patent/BR112019017713A2/pt not_active Application Discontinuation
- 2018-02-27 KR KR1020197027869A patent/KR20190124247A/ko not_active Ceased
- 2018-02-27 US US16/484,853 patent/US11267856B2/en active Active
- 2018-12-18 US US16/223,332 patent/US10513548B2/en active Active
-
2019
- 2019-06-28 PH PH12019501534A patent/PH12019501534A1/en unknown
- 2019-07-21 IL IL268197A patent/IL268197A/en unknown
- 2019-08-25 SA SA519402522A patent/SA519402522B1/ar unknown
- 2019-09-20 ZA ZA2019/06235A patent/ZA201906235B/en unknown
- 2019-11-06 US US16/675,475 patent/US11267857B2/en active Active
-
2022
- 2022-01-28 US US17/587,447 patent/US20220144909A1/en not_active Abandoned
- 2022-08-04 JP JP2022125121A patent/JP2022159393A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508063A5 (enExample) | ||
| JP5798919B2 (ja) | Ｐｄ−１アンタゴニストの組成物および使用方法 | |
| US10329338B2 (en) | Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon | |
| Qui et al. | CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation | |
| KR101471647B1 (ko) | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 | |
| JP2020508068A5 (enExample) | ||
| TWI850282B (zh) | 用於治療癌症之質體建構體和使用方法 | |
| KR20160093012A (ko) | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 | |
| JP2020508329A5 (enExample) | ||
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| JP6682438B2 (ja) | 癌治療のための改善された細胞組成物および方法 | |
| US10463731B2 (en) | Adjuvant combinations comprising alpha-galactosylceramide or iGb3, CD40 agonists and antigen | |
| JP2022527643A (ja) | がん治療のための免疫療法 | |
| JP2020508066A5 (enExample) | ||
| WO2013062365A2 (ko) | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 | |
| WO2018039332A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
| RU2832189C2 (ru) | Антигенный рецептор | |
| Pishesha et al. | Single domain antibody-antigen adducts that target Class II MHC induce antigen-specific tolerance | |
| RU2019129835A (ru) | Химерные белки на основе csf1r | |
| TW202543675A (zh) | 死亡受體５（ｄｒ５）－裝甲之ｃａｒ－ｔ治療劑 | |
| Tao et al. | IL-21 Enhances and Sustains CD8 | |
| CN111936616A (zh) | 改进的αβT加工细胞的制备方法 |